329 Studies Now Enrolling
Menu
Search
Medical Condition
- Show all (329)
- Addiction (4)
- Allergy, Asthma, & Immunology (1)
- Autoimmune Disorders (3)
- Blood Disorders (2)
- Bone & Muscle (2)
- Cancer (83)
- COVID-19 (Coronavirus) (8)
- Diabetes (6)
- Ear, Nose and Throat (6)
- Endocrine & Metabolic Disease (2)
- Gastrointestinal and Digestive Diseases (5)
- Hair and Skin Disorders (2)
- Healthy Volunteers (46)
- Heart Disease (22)
- Infectious Disease (11)
- Liver Disease (14)
- Lung Disease (2)
- Neurological Disorders (41)
- Nutrition (1)
- Obesity (9)
- Obstetrics & Gynecology (12)
- Pediatrics (20)
- Psychiatric Disorders (7)
- Rehabilitation (1)
- Stroke (2)
- Transplant (16)
- Vascular Conditions (1)
Displaying 1 - 8 of 8
Condition: Cancer / Prostate Cancer
Investigator: Alexander Wei, MD
Status: Currently Recruiting
The purpose of this trial is to learn more about an investigational drug called DS9051b. DS9051b is an investigational drug that is not Food and Drug Administration (FDA) approved for your disease. This is a first in human study. It is being studied to see if it is safe, and if your disease improves while taking it.
Condition: Cancer / Multiple Myeloma
Investigator: Rajshekhar Chakraborty, MD
Status: Currently Recruiting
This study is looking at people who have recently been newly diagnosed with a type of cancer called multiple myeloma (NDMM). The purpose of this study is to learn about the safety, tolerability (how your body reacts to the study drug), and effectiveness (tumor shrinkage) of linvoseltamab (called study drug) in participants with NDMM as a first step in…
Condition: Cancer / Prostate Cancer
Investigator: Mark Stein, MD
Status: Currently Recruiting
The purpose of this study is to determine the safety, tolerability (how your body reacts to the drug) and effectiveness of REGN5678 which will be given alone first and then be given in combination with cemiplimab. Neither REGN5678 nor Cemiplimab is FDA-approved to treat your type of cancer. Cemiplimab is approved by the FDA for the treatment of certain…
Condition: Cancer / Multiple Myeloma
Investigator: Rajshekhar Chakraborty, MD
Status: Currently Recruiting
This study is the first time REGN5458 will be combined with other cancer therapies. The main goal is to understand if REGN5458 can be given safely with other cancer study treatments, and if so, what dose of REGN5458 should be used for each combination. The investigational drug, REGN5458, is not approved by the Food and Drug Administration (FDA).
Condition: Cancer / Multiple Myeloma
Investigator: Rajshekhar Chakraborty, MD
Status: Currently Recruiting
The purpose of the study is to determine the proportion of patients with lowest minimal residual disease (MRD) response obtainable after receiving 6 cycles of study treatment. Minimal residual disease is multiple myeloma cells below the level of 1 cancer cell out of 100,000 in the bone marrow. For patients who are MRD "positive" at the end of 6…
Study of Daratumumab in Addition to Chemotherapy for Patients with Smoldering Multiple Myeloma (SMM)
Condition: Cancer / Multiple Myeloma
Investigator: Rajshekhar Chakraborty, MD
Status: Currently Recruiting
The purpose of this study is to determine whether patients with high-risk smoldering multiple myeloma when treated with daratumumab in addition to lenalidomide and dexamethasone live longer when compared to patients with high-risk smoldering multiple myeloma patients treated with lenalidomide and dexamethasone. We would also like to know whether the period…
Condition: Cancer / Prostate Cancer
Investigator: Mark Stein, MD
Status: Currently Recruiting
The purpose of this study is to find out the side effects of JNJ-87189401 given in combination with JNJ-78278343 to patients with metastatic castration-resistant prostate cancer, and to find which doses of the two study drugs when given in combination cause the least side effects. The study will also look at how long JNJ-87189401 and JNJ-78278343 stay in…
Condition: Cancer / Multiple Myeloma
Investigator: Rajshekhar Chakraborty, MD
Status: Currently Recruiting
The purpose of this study is assess safety, safest dose, and effectiveness of venetoclax in combination with dexamethasone in subjects with t(11;14) positive relapsed (comes back) or refractory (did not get better) light chain amyloidosis. Furthermore, the purpose of phase 2 part of this study is to compare the effectiveness of venetoclax and dexamethasone…
This website uses cookies as well as similar tools and technologies to understand visitors’ experiences. By continuing to use this website,
you consent to Columbia University’s usage of cookies and similar technologies, in accordance with the
Columbia University Website Cookie Notice.
I AGREE